Conditions: Type 2 Diabetes
Keywords: DPP-4 inhibitors HbA1c incretins Renal Impairment
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 572
Healthy volunteers: no

Brief summary:
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.

Detailed description:

Arms:
arm 1: Saxagliptin arm 2: Placebo to match

Interventions: intervention 1: Saxagliptin intervention 2: Placebo
Intervention descriptions: intervention 1: 2.5 mg once daily oral dose intervention 2: Placebo

Protocol document: